Breast Cancer Diagnostics Market Overview
Breast Cancer Diagnostics Market accounted for US$ 4.5 billion in 2022 and is estimated to be US$ 9.10 billion by 2032 and is anticipated to register a CAGR of 7.5%.
Breast cancer are of different types like, DCIS (Ductal carcinoma in situ), Phyllodes tumor, Paget disease of the breast, Triple-negative breast cancer, Invasive breast cancer, Angiosarcoma, and Inflammatory breast cancer. DCIS breast cancer is curable. Symptoms of breast cancer are, thickening and swelling of part of breast, pain in nipple area, redness or flaky skin in nipple area, new lump in the breast or armpit, irritation or dimpling of breast skin, nipple discharge other than breast milk, nipple retraction, breast pain, bumps, growing veins on breast, skin sores, etc. Breast cancer starts when some breast cells begin to grow abnormally, then these cells divide rapidly and accumulate to form lumps. Breast cancers are found in women who are older or around fifty years old. Breast cancer can also occurs in age of 20s or 30s so early diagnosis and treatment is must. Breast cancer screening is the process of checking women’s breasts for cancer before getting any abnormal symptoms or signs of disease.
Screening methods of breast cancer are mammography which is common method and MRI (Magnetic Resonance Imaging) used in screening at high risk of breast cancer. Screening test studied in clinical trials are tissue sampling, thermography, and breast exam. Mammogram is commonly used and first test for screening of breast cancer. Around 80% of women are diagnosed with breast cancer at age of 45 and older. Radiation exposure, family history, obesity, personal history of breast conditions, inherited genes which increase cancer risk, increasing age are some risk factors of getting breast cancer. Women having breast cancer should avoid alcohol, caffeine, soft-cooked eggs, unwashed fruits and vegetables, raw meat, fish, unpasteurized dairy product or juice, etc. Exposure to radiation, unhealthy lifestyle, older age and personal history has increased risk of breast cancer which has given rise in Breast Cancer Diagnostics growth.
Breast Cancer Diagnostics Market Drivers & Restraints
Rise in incidence of breast cancer and rate of urbanization
Rise in incidence of breast cancer and rate of urbanization is one of the leading factors for the Global Breast Cancer Diagnostics Market growth. Urbanization has given rise in consumption of western food, processed food, frozen packed foods, alcohol, caffeine, which are unhealthy and affected the health of human being. Urbanization has given rise in disposable income which allows the individual to enhance their lifestyle, spending less on cereals, millets, fruits, vegetables, spending more on processed foods and beverages, consuming high amount of red meat and animal derived food, fats & oils, sugar, sodium, which has affected the health. Urbanization has caused unhealthy lifestyle, change in diet, obesity, lack of exercise, pollution, late marriages fewer children, no breast feeding or lesser feeding for less duration, early menarche, late menopause, which has become major contribution in global rise of breast cancer. According to ‘The World Cancer Report 2020’ it was determined that incidence of breast cancer is consistently rising in India due to high socio-economic status and rapid urbanization. For instance, in 2016, (NIH), the relationship between cancer incidence and urbanization in Iran were conducted by using Quantile Regression. Data obtained by Ministry of Health & Medical Education and relationship between urbanization and cancer morbidity was investigated by quantile regression and determined that breast cancers, pancreas, prostate, colorectal and lung cancers increasing with rate of urbanization. 90th percentile was maximum increase rate of breast cancer. 95th percentile was of prostate cancer, 75th percentile was of colorectal cancer, 95th percentile for lung cancer and 10th percentile for pancreas cancer. According to the results, it was determined that there was significant impact of rising urbanization on cancer morbidity due to risk factors like more pollution in urban areas, poor nutrition food, lack of exercise, smoking, alcohol intake, etc. According to data published by United Nations in 2018, about 55% of the world’s population resided in urban areas, and it is projected that this percentage will increase over the forecast period. However, the growth in breast cancer and population in urban areas boosts the demand for Breast Cancer Diagnostics market.
Technological advancement
Technological advancement in diagnostic treatment has become major factor in target market growth. Advances in 3D mammography has created new opportunities in improvement of screening and early detection of breast cancer. 3D mammographywhich is also called as ‘breast tomosynthesis’ is the procedure which takes images around breast from different angles and build them in 3D image. Scintimammography (molecular breast imaging), Electrical Impedance Imaging and Positron Emission Mammography (PEM) are currently explored new diagnostic methods in imaging testing. PEM is newer imaging test in diagnosing breast cancer that combines aspects of mammogram and PET scan. PEM uses same radioactive tracer injected into blood as a PET scan then breast are lightly compressed while taking images with mammogram. For instance, in 2021, newly advanced ‘Artificial Intelligence’ technology is used in breast cancer detection. Advanced ‘Artificial Intelligence’ technology has provide medical professionals to sort through breast MRI’s in patients with dense breast tissue more quickly and accurately to eliminate those without cancer. An ‘Artificial Intelligence’ technology has reduced the radiologist’s workload. However, new technological advancement in detection of breast cancer has fueled the target market growth.
Restrains of Breast Cancer Diagnostics Market:
However, lack of awareness regarding test, lack of qualified human resource with minimal training, one radiologists is available for every 100,000 population, incorrect results, technical issues, limitations in technology as there is low sensitivity in younger women with dense breast, radiation and pain during detection may somewhat restrain the Breast Cancer Diagnostics market growth.
Breast Cancer Diagnostics Market Segmentations & Regional Insights
Breast Cancer Diagnostics Market is segmented based on test, application, end-users and region.
Ingredients Insight
On the basis of Test Breast Cancer Diagnostics Market is segmented into Mammogram, Blood Test, Breast Magnetic Resonance Imaging (MRI), Biopsy, Breast Ultrasound, and others. Mammogram has dominated the target market as it is most commonly used method in detection of breast cancer.
Application Insights
On the basis of Application Breast Cancer Diagnostics Market is segmented into Research, Screening, Prognostic, and others. Screening has dominated the target market as it is earlier detection before development of abnormal signs and symptoms of breast cancer.
End-Users
On the basis of End-Users Breast Cancer Diagnostics Market is segmented into Clinics, Hospitals, Medical Laboratories, Diagnostic Centers, and others. Diagnostic Centers has dominated the target market due to rising awareness among people in earlier diagnosis and test.
Regional Insights:
On region the Breast Cancer Diagnostics Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific market is estimated to witness a significantly high revenue share over the forecast period, owing to growing population, especially in countries such as Europe and Asia Pacific, and technological advancements. Moreover, rising incidence of breast cancer, rising diagnostic centers, awareness of earlier diagnosis among women, increase in adoption of Precision medicine is anticipated to increase demand for Breast Cancer Diagnostics in the region.
Breast Cancer Diagnostics Market Report Scope:
Attribute |
Details |
Base year for estimation |
2022 |
Forecast period |
2022 – 2032 |
Market representation |
Revenue in USD Billion & CAGR from 2022 to 2032 |
Market Segmentation |
By Test - Mammogram, Blood Test, Breast Magnetic Resonance Imaging (MRI), Biopsy, Breast Ultrasound, and others By Application - Research, Screening, Prognostic, and others By End-Users - Clinics, Hospitals, Medical Laboratories, Diagnostic Centers, and others
|
Regional scope |
North America - U.S., Canada Europe - UK, Germany, Spain, France, Italy, Russia, Rest of Europe Asia Pacific - Japan, India, China, South Korea, Australia, Rest of Asia-Pacific Latin America - Brazil, Mexico, Argentina, Rest of Latin America Middle East & Africa - South Africa, Saudi Arabia, UAE, Rest of Middle East & Africa |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segments Covered in the Report:
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2022 to 2032. For the purpose of this study, has segmented the Global Breast Cancer Diagnostics Market report based on test, application, end-users and region:
Breast Cancer Diagnostics Market, By Test:
- Mammogram
- Blood Test
- Breast Magnetic Resonance Imaging (MRI)
- Biopsy
- Breast Ultrasound
- Others
Breast Cancer Diagnostics Market, By Application:
- Research
- Screening
- Prognostic
- Others
Breast Cancer Diagnostics Market, By End-Users:
- Clinics
- Hospitals
- Medical Laboratories
- Diagnostic Centers
- Others
Breast Cancer Diagnostics Market, By Region:
- North America
- U.S.
- Canada
- Europe
- Germany
- UK
- France
- Russia
- Italy
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
Breast Cancer Diagnostics Market Competitive Landscape & Key Players
The key players operating the Breast Cancer Diagnostics Market includes,
QIAGEN
It is the U.S. largest diagnostic company which helps in delivering novel treatment in breast cancer.
Danaher Corporation
It is the developer and distributor of technologies in breast cancer care.
Myriad Genetics Inc.
It is the leader in precision medicine and genetic testing offering innovative products. It offers testing for inherited cancers like breast, colon, uterine, ovarian, prostate cancer and others.
Quest Diagnostics Incorporated
It is the complete portfolio of hereditary cancer tests and services.
NanoString
It provides tools for studying impact of changes in genome of cancer, tumor biology, detect RNA fusions, and others.
Hologic Inc.
It is the leading innovator in women’s health. It offers products for accurate detection and treatment of breast and skeletal health, etc.
Argon Medical Devices Inc.
It is the manufacturer of medical devices for diagnosis of breast cancer, vascular surgery, cardiology, etc.
Thermo Fisher Scientific Inc.
It offers diagnostic testing instruments and solutions in cancer and other diseases.
QIAGEN
It is the U.S. largest diagnostic company which helps in delivering novel treatment in breast cancer.
F. Hoffman-La Roche Ltd.
It offers breast cancer diagnostic solutions.
GE Healthcare
It offers diagnostic tools for cancer such as breast cancer and leukemia.
Breast Cancer Diagnostics Market Recent News
- In May 2022, Myriad Genetics has launched new comprehensive suite of cancer test Mychoice CDx and Bracanalysis CDx with research registry and designed for personalized chemotherapy treatment.
- In May 2021, GE Healthcare announced the acquisition of Zionexa and leading innovator of neurology biomarkers and in-vivo oncology that enable personalized healthcare. It has aimed in developing Zionexa’s pipeline biomarkers and FDA approved PET imaging agent, Cerianna in detection of recurrent or metastatic breast cancer.
Breast Cancer Diagnostics Market Company Profile
- Myriad Genetics Inc.*
- Company Overview
- Product Portfolio
- Key Highlights
- Financial Performance
- Business Strategies
- QIAGEN
- Danaher Corporation
- Quest Diagnostics Incorporated
- NanoString
- Hologic Inc.
- Argon Medical Devices Inc.
- Thermo Fisher Scientific Inc.
- F. Hoffman-La Roche Ltd.
- GE Healthcare*
“*” marked represents similar segmentation in other categories in the respective section
Breast Cancer Diagnostics Market Highlights
FAQs
The Breast Cancer Diagnostics Market is segmented into test, application, end-users, and region.
Breast Cancer Diagnostics Market is driven by factors like rise in incidence of breast cancer, rate of urbanization, and technological advancement.
By region, the Breast Cancer Diagnostics market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The Asia Pacific market is estimated to witness a significantly high revenue share over the forecast period, owing to growing population, especially in countries such as Europe and Asia Pacific, and technological advancements.
The key players operating the Breast Cancer Diagnostics Market includes, QIAGEN, Danaher Corporation, Myriad Genetics Inc., Quest Diagnostics Incorporated, NanoString, Hologic Inc., Argon Medical Devices Inc., Thermo Fisher Scientific Inc., F. Hoffman-La Roche Ltd., GE Healthcare and others.